Detailed presentation of the Cancer & the Kidney International Network. Partnership opportunities.

1. Cancer & the Kidney
International Network
Dr. Vincent LAUNAY-VACHER
C-KIN President
Service ICAR
Pitié-Salpêtrière University Hospital, Paris, France
vincent.launay-vacher@psl.aphp.fr

2. First C-KIN
Annual
Conference
14-15 April 2015 !
www.c-kin.org
2

3. Rationale
 Is there any need for Cancer & Kidney disease
Education and Research ?
3

4. CKD is highly prevalent in
cancer patients (solid tumours)
 France1,2: IRMA studies (1 and 2)
 4’684 et 4’945 patients (all types of solid tumours)
 eGFR<60 : 12.0% et 11.8%
 Belgium3: BIRMA study
 1’218 patients (all types of solid tumours)
 eGFR<60 : 16.1%
 United States4:
 1’114 patients (kidney cancer)
 eGFR<60 : 22,0%
 Japan5:
 231 patients (all types of solid tumours)
 eGFR<60 : 25.0%
41Launay-Vacher V et al. Cancer 2007; 2Launay-Vacher V et al. Semin Nephrol 2010; 3Janus N et al. Br J Cancer 2010;
4Canter D et al. Urology. 2011; 5Nakamura Y et al. Nihon Jinzo Gakkai Shi. 2011;
CKD: Chronic Kidney Disease
eGFR: estimated Glomerular Filtration Rate

5. CKD is a risk factor for death in
cancer patients (solid tumours)
 France1:
 eGFR<60 => reduced overall survival HR 1.27 (p=0.0002)
 Japan2 :
 eGFR<60 = independent risk factor for death at 1 year
 Korea3 :
 30<eGFR<60 => HR for death 1.12 (p=0,04)
 eGFR<30 => HR for death 1.75 (p<0,001)
51Launay-Vacher V et al. Semin Nephrol 2010;
2Nakamura Y et al. Nihon Jinzo Gakkai Shi. 2011;
3Na SY, et al. Am J Nephrol. 2011

6. CKD is a risk factor for death in
cancer patients (solid tumours)
1Launay-Vacher V et al. Semin Nephrol 2010;
2Na SY, et al. Am J Nephrol. 2011
6
aMDRD ≥ 60 (n=3720)
aMDRD < 60 (n=547)
p<0.0001
Ref. 1 Ref. 2
Cancer-related mortality
Reduced overall survival Increased cancer-related
mortality

7. CKD is a risk factor
for cancer death
71Iff S, et al. Am J Kidney Dis 2014
 Population-based Australian study1:
 4’077 patients, median follow-up of 12.8 years
 eGFR<60 : independent risk factor for cancer death (CKD-EPI)
 HR for cancer-related death = 1.27
 Breast cancer: HR = 1.99
 Urothelial cancers: HR = 2.54
 Significant relationship between eGFR and cancer mortality
 Each  in eGFR of 10 ml/min/1.73m2 = 18%  of cancer mortality (p=0.001)
Among patients with cancer
eGFR ≥ 75: Reference
eGFR 60-74: adjusted HR 1.55 [1.09-2.20]
eGFR 45-59: adjusted HR 1.42 [0.96-1.40]
eGFR < 45: adjusted HR 2.29 [1.43-3.69]

8. Rationale
 Is there any need for Cancer & the Kidney
Education and Research ?
 YES: CKD is highly prevalent in cancer patients
 YES: CKD is associated with higher mortality
 Reduced overall survival
 Increased cancer-specific mortality
 MARCH 2014: World Kidney Day
 Official launch of the Cancer & the Kidney International
Network
8

9. Natural history of
« Cancer & the Kidney »
9
2005
Textbook
« Cancer and the Kidney »
1st Ed.
Oxford University Press
2007
1Launay-Vacher et al. 2010
4Launay-Vacher et al.
5Janus et al.
1Launay-Vacher V, et al. Cancer. 2007;110:1376-84; 2Launay-Vacher V. et al. Ann Oncol. 2007;18:1314-21; 3Lichtman SM. et al. Eur J Cancer. 2007;43:14-34; 4Launay-
Vacher V, et al. Semin Nephrol. 2010;30:548-56; 5Janus N, et al. Br J Cancer. 2010;103:1815-21; 6Canter D, et al. Urology. 2011;77:781-5; 7Nakamura Y, et al. Nihon Jinzo
Gakkai Shi. 2011;53(1):38-45; 8Na SY, et al. Am J Nephrol. 2011;33:121-30; 9Launay-Vacher V. Ann Oncol. 2013;24:2713-4
2011
6Canter et al.
7Nakamura et al.
8Na et al.
2013
9Invited Editorial
Annals of Oncology
2011
Textbook
« Cancer and the Kidney »
2nd Ed.
Oxford University Press
2014
ESO (European School of Oncology)
Special Course
« Cancer & the Kidney »
ResearchAwarenessEducation
2007
SIOG Guidelines
2Launay-Vacher et al.
3Lichtman et al.

10. C-KIN ORGANISATION
 Not-for-profit organization
 Executive Committee:
 Vincent Launay-Vacher, France – President
 Ben Sprangers, Belgium (Nephrology) – Treasurer
 Matti Aapro, Switzerland (Oncology) – Secretary
 Governing Board
 Gilberto de Castro Jr, Brazil (Nephrology)
 Eric Cohen, USA (Nephrology)
 Gilbert Deray, France (Nephrology)
 Michael Dooley, Australia (Clinical Pharmacy)
 Benjamin Humphreys, USA (Nephrology)
 Stuart Lichtman, USA (Oncology)
 Jean-Baptiste Rey, France (Clinical Pharmacy)
 Florian Scotté, France (Oncology)
 Hans Wildiers, Belgium (Oncology)
10

11. C-KIN MEMBERSHIP
 The aim of C-KIN is to improve patient care
 Target audience thus includes all healthcare
professionnals involved and/or interested in:
 The care of renal insufficiency cancer patients
 The improvement of chemotherapies/targeted therapies renal
safety
 The nephro-oncology multidisciplinary care of these patients
 The pharmacological aspects and consequences of renal
insufficiency/kidney disease on recent or older oncology
drugs efficacy/safety
11

12. C-KIN MEMBERSHIP
 The aim of C-KIN is to improve patient care
 Target audience thus includes:
 Oncologists
 Hematologists
 Supportive Care in Cancer specialists
 Nephrologists
 Radiotherapists
 Clinical Pharmacists
 …/…
12

13. C-KIN ENDORSMENTS
 C-KIN is officially endorsed by
 4 joint sessions at C-KIN 2015 Annual Conference
13

14. C-KIN MISSION
Improving cancer patients care through better
knowledge on cancer and the kidney related issues,
through:
 Education
 Research
 Practical tools
14

15. C-KIN MISSION
Improving cancer patients care through better
knowledge on cancer and the kidney related issues,
through:
 Education
 1st C-KIN Annual Conference, 14-15 April 2015, Brussels, BE
 Literature monitoring (Members Library)
 E-Learning program (in development)
15

16. C-KIN Conference 2015
 1st C-KIN Annual Conference is endorsed by:
 European Continuous Medical Education
accreditation is currently being submitted to:
 The European Accreditation Council for Continuing Medical
Education – EACCME®
16

17. C-KIN Conference 2015
17
 1st Annual Conference
 2 days of Education and Networking
 3 Plenary Sessions
 4 joint sessions with:
 ASCO (American Society of Clinical Oncology)
 EAHP (European Association of Hospital Pharmacists)
 EORTC (European Organization for the Research and Treatment of Cancer)
 SIOG (International Society of Geriatric Oncology)
 5 Oral Communication and Posters
sessions
 60 abstracts accepted
 12 countries

18. C-KIN Conference 2015
 Plenary 1. Cancer & the Kidney: Theory to Practice
 How to Evaluate the Renal Function in Cancer Patients
 How to Dose Carboplatin in CKD?
 Cisplatin Renal Toxicity Prevention
 Plenary 2. Targeted Therapies & the Kidney
 Comparative Renal Safety Profiles of New and Ancient Cancer Therapies
 BRAF in the Kidney: Does the target Make the Damage?
 Renovascular Safety of Antiangiogenics: Update from the C-KIN Working Group
 Plenary 3. Supportive Care & the Kidney
 Anemia in Cancer Patients with CKD
 The Specific Role of Antiemetics in Kidney Protection
 Venous Thromboembolism, Cancer, and CKD : Update from C-KIN Working Group
18

19. C-KIN Conference 2015
 Countries of speakers for Plenaries and Main program sessions
 France (8)
 Belgium (3)
 USA (3)
 Switzerland (2)
 Germany (1)
 Netherlands (1)
 UK (1)
 Countries of abstract presenters (oral or posters)
 France (14)
 USA (12)
 Belgium (11)
 Italy (5)
 Brazil (4)
 .../...
19

20. C-KIN MISSION
Improving cancer patients care through better
knowledge on cancer and the kidney related issues,
through:
 Research
 Joint Renal task force with EORTC
(European Organization for the Research and Treatment of Cancer)
 First research project ongoing
 Collaboration with EMA (European Medicine Agency)
 Developing C-KIN clinical studies
20

21. C-KIN MISSION
Improving cancer patients care through better
knowledge on cancer and the kidney related issues,
through:
 Practical tools
 C-KIN membership includes a free access to SiteGPR®
(website providing evidence-based recommendations on drugs dosage adjustments in CKD)
 Online estimation of renal function:
 Simultaneous Cockcroft-Gault, MDRD, CKD-EPI
 Automatic conversion from ml/min/1.73m2 into ml/min
 800 drugs with dosage adjustment recommendations based on
the international literature
 Clinical practice guidelines:
 Developed within working groups activities
21

22. C-KIN Working Groups
 2014-2015
 1) Thrombosis, Cancer, and CKD
 6 experts from Europe and Canada
 Clinical practice guidelines expected end 2015
 2) Antiangiogenics’ renovascular safety
 Same organization
 2015-2016
 1) CINV prevention and cancer drugs renal toxicity
 2) Anemia in cancer patients
22

23. Other organizations
on the same topic ?
 American Society of Nephrology:
 The Onco-Nephrology Forum (ONF)
 Discussions between ONF and C-KIN
 Several members in common
23
ONF C-KIN
USA International
Nephrologists Multidisciplinary
Basic science &
physiopathology
Clinically-oriented
Both organizations are not competing,
they are complementary

24. C-KIN Partnerships
 C-KIN Corporate Membership
 See « CKIN Corporate Member Benefits »
 C-KIN 2015 Conference Sponsor
 See « CKIN_Conference_Partnership_Opportunities_2015 »
24

25.  Partner with C-KIN to improve cancer patients’ care
 25 to 40% of cancer patients have CKD
 Cancer-related mortality more than doubled
 There is much to do !
Dr. Vincent LAUNAY-VACHER
C-KIN President
Service ICAR
Pitié-Salpêtrière University Hospital Paris,
France
vincent.launay-vacher@psl.aphp.fr
C-KIN Global Headquarters
300 Avenue de Tervueren
1150 Brussels, Belgium
Tel : +32 (0)2 743 15 44
info@c-kin.org